ORION-4 trial

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

The ongoing cardiovascular outcome trial for Inclisiran, anticipated to show reduction in major adverse cardiovascular events due to LDL lowering.